login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Medindia »
Consumer Health »
Health Information »
Latest Publication and Research on Clinical Trials - Different Phases of the trial
| Disease Info Index | ||||||||||||||||||||||||||
|
|
Clinical Trials - Different Phases of the trial
Page Options
Clinical Trials - Different Phases of the trial
Latest Publication and Research on Clinical Trials - Different Phases of the trial
|
|
|
Text 
|
2011 Nov 7 Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2-Phase Randomized Controlled Trial. Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN, Haller DL, Hasson AL, Huang Z, Jacobs P, Kosinski AS, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W McLean Hospital, Belmont (Drs Weiss, Potter, Connery, and Griffin and Mr Provost), Department of Psychiatry, Harvard Medical School, Boston (Drs Weiss, Potter, Connery, and Griffin) and NIDA CTN (The National Institute on Drug Abuse Clinical Trials Network) New England Consortium Node, Belmont (Drs Weiss, Potter, Fiellin, Connery, and Griffin, and Mr Provost), Massachusetts; Department of Psychiatry, University of Texas Health Science Center at San Antonio, and NIDA CTN Texas Node, Dallas (Dr Potter); Department of General Internal Medicine, Yale University School of Medicine, New Haven, Connecticut (Dr. Fiellin); Chestnut Ridge Hospital, Department of Behavioral Medicine and Psychiatry, West Virginia School of Medicine, Morgantown, and NIDA CTN Appalachian Tri-State Node, Pittsburgh, Pennsylvania (Ms Byrne); Providence Regional Medical Center, Everett, and NIDA CTN Pacific Northwest Node, Seattle, Washington (Dr Dickinson); Adapt, Inc, Roseburg, Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland, and NIDA CTN Western States Node, Portland, Oregon/San Francisco, California (Dr Gardin); Bellevue Hospital and the Division of General Internal Medicine and Department of Psychiatry, New York University School of Medicine (Dr Gourevitch), and NIDA CTN Greater New York Node, New York, New York (Drs Gourevitch, Haller, and Selzer), and Division of Clinical Research, Departments of Psychiatry, St Luke's Roosevelt Hospital Center and Columbia University College of Physicians and Surgeons, New York, New York (Dr Haller); UCLA Integrated Substance Abuse Programs and NIDA CTN Pacific Region Node, Los Angeles, California (Mr Hasson); Duke Clinical Research Institute, Durham, North Carolina (Ms Huang); NIDA CTN, Bethesda, Maryland (Dr Jacobs); Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina (Dr Kosinski); The EMMES Corporation, Rockville, Maryland (Dr Lindblad); San Francisco General Hospital, Department of Psychiatry, University of California, San Francisco; NIDA CTN Western States Node, Portland, Oregon/San Francisco, California (Dr McCance-Katz); North Shore Long Island Jewish Health System and Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, New York, New York (Dr. Selzer); Department of Psychiatry and Behavioral Neurosciences, University of Cincinnati, Department of Veterans Affairs Medical Center, Cincinnati, Cincinnati Addiction Research Center, and NIDA CTN Ohio Valley Node, Cincinnati, Ohio (Dr Somoza); Clinical Neuroscience Division, Medical University of South Carolina and NIDA CTN Southern Consortium Node, Charleston, South Carolina (Dr Sonne); and UCLA Integrated Substance Abuse Programs, Department of Psychiatry and Behavioral Sciences, David Geffen School of Medicine at UCLA, and NIDA CTN Pacific Region Node, Los Angeles, California (Dr Ling). CONTEXT: No randomized trials have examined treatments for prescription opioid dependence, despite its increasing prevalence. OBJECTIVE: To evaluate ... Read More Source: PubMed 2011 Nov 7 Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2-Phase Randomized Controlled Trial. Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin ML, Gourevitch MN, Haller DL, Hasson AL, Huang Z, Jacobs P, Kosinski AS, Lindblad R, McCance-Katz EF, Provost SE, Selzer J, Somoza EC, Sonne SC, Ling W McLean Hospital, Belmont (Drs Weiss, Potter, Connery, and Griffin and Mr Provost), Department of Psychiatry, Harvard Medical School, Boston (Drs Weiss, Potter, Connery, and Griffin) and NIDA CTN (The National Institute on Drug Abuse Clinical Trials Network) New England Consortium Node, Belmont (Drs Weiss, Potter, Fiellin, Connery, and Griffin, and Mr Provost), Massachusetts; Department of Psychiatry, University of Texas Health Science Center at San Antonio, and NIDA CTN Texas Node, Dallas (Dr Potter); Department of General Internal Medicine, Yale University School of Medicine, New Haven, Connecticut (Dr. Fiellin); Chestnut Ridge Hospital, Department of Behavioral Medicine and Psychiatry, West Virginia School of Medicine, Morgantown, and NIDA CTN Appalachian Tri-State Node, Pittsburgh, Pennsylvania (Ms Byrne); Providence Regional Medical Center, Everett, and NIDA CTN Pacific Northwest Node, Seattle, Washington (Dr Dickinson); Adapt, Inc, Roseburg, Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland, and NIDA CTN Western States Node, Portland, Oregon/San Francisco, California (Dr Gardin); Bellevue Hospital and the Division of General Internal Medicine and Department of Psychiatry, New York University School of Medicine (Dr Gourevitch), and NIDA CTN Greater New York Node, New York, New York (Drs Gourevitch, Haller, and Selzer), and Division of Clinical Research, Departments of Psychiatry, St Luke's Roosevelt Hospital Center and Columbia University College of Physicians and Surgeons, New York, New York (Dr Haller); UCLA Integrated Substance Abuse Programs and NIDA CTN Pacific Region Node, Los Angeles, California (Mr Hasson); Duke Clinical Research Institute, Durham, North Carolina (Ms Huang); NIDA CTN, Bethesda, Maryland (Dr Jacobs); Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina (Dr Kosinski); The EMMES Corporation, Rockville, Maryland (Dr Lindblad); San Francisco General Hospital, Department of Psychiatry, University of California, San Francisco; NIDA CTN Western States Node, Portland, Oregon/San Francisco, California (Dr McCance-Katz); North Shore Long Island Jewish Health System and Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, New York, New York (Dr. Selzer); Department of Psychiatry and Behavioral Neurosciences, University of Cincinnati, Department of Veterans Affairs Medical Center, Cincinnati, Cincinnati Addiction Research Center, and NIDA CTN Ohio Valley Node, Cincinnati, Ohio (Dr Somoza); Clinical Neuroscience Division, Medical University of South Carolina and NIDA CTN Southern Consortium Node, Charleston, South Carolina (Dr Sonne); and UCLA Integrated Substance Abuse Programs, Department of Psychiatry and Behavioral Sciences, David Geffen School of Medicine at UCLA, and NIDA CTN Pacific Region Node, Los Angeles, California (Dr Ling). CONTEXT: No randomized trials have examined treatments for prescription opioid dependence, despite its increasing prevalence. OBJECTIVE: To evaluate ... Read More Source: PubMed |
| Share it! |  |
 |
 |
 |
 |
 |
 |
|
|
Comment & Contribute
|
|
| Citing this Health Article | ||||||
|
||||||
| News on Clinical Trials - Different Phases of the trial |
|
Canada Must Step Up Funding for Randomized Clinical Trials |
|
New Drug That Only Attacks Cancer Cells Developed |
|
Heat Shock Protein Inhibitor And Hormonal Therapy Combo Tested in Breast Cancer Clinical Trial |
|
Verify Clinical Trials of Non-Skeletal Benefits Of Vitamin D, Demand Experts |
|
Clinical Trials into New Drug Targeting Abnormal Genes Responsible for Cancer Provide Encouraging Results in Phase I Trial |
| Total News Item 528 | |
Are you a member of Facebook? Become a fan of Medindia and get breaking news delivered to your Facebook page.
- Market Trends
- Growth Drivers
- Regulatory Bodies and Framework
- Major Players.
-Etc.
We interviewed over 200 individuals and firms to collect the data in what we believe is one of the most detailed study on the subject in India.